Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$27,000.00
Mapping the single cell specific signaling mechanisms required for the activity of CFTR in patients affected by Cystic Fibrosis
EF 2024-25
Résumé
My research is focused on improving the scope of available therapeutics for patients with Cystic Fibrosis (CF). CF is a severe disease caused by the loss of a key protein called CFTR (Cystic Fibrosis Transmembrane Conductance Regulator), which results in an improper mucus layer lining patient airways and impairs lung function. A novel therapeutic known as Trikafta, has proven much success in ameliorating the symptoms of CF in patients by targeting the CFTR protein directly. However, there remains a cohort of patients who are unresponsive to Trikafta treatment and are therefore in desperate need of novel therapeutics. We hypothesize that the development of novel companion therapies will act synergistically with Trikafta.
The tissues that line our airways are made up of many distinct cell types which contain the CFTR protein. Data collected by our laboratory revealed distinct cell types enriched in the CFTR protein as well as distinct partner proteins. However, it remains unknown how these unique cell types work to utilize these distinct proteins to maintain proper CFTR function. We believe that an improved understanding of this cell type specific regulation of CFTR will uncover novel druggable protein targets. I will utilize airway tissue models from real CF patients, which have been heavily validated by our laboratory, as the model for CFTR activity. I will use specialized microscopy techniques on these cultures to detect for the presence of distinct cell types and monitor the functional augmentation of CFTR relative to modulators of these distinct partnering proteins. Ultimately, these novel drug targets have the potential to work in synergy with currently available therapeutics to ameliorate the symptoms of CF in the non-responsive cohort of patients.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
536472
Name
D'Addario Chiara M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Mapping the single cell specific signaling mechanisms required for the activity of CFTR in patients affected by Cystic Fibrosis
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Calcium Signaling; Cell Type Specific Fluorescent Labelling; Cell Type Specific Signaling Mechanisms; Cystic Fibrosis; Intercellular Communication; Microscopy; Precision Child Health; Primary Human Nasal Cultures; Single Cell Rna Sequencing; Small Molecule Fluorescent Probes
Abstract
My research is focused on improving the scope of available therapeutics for patients with Cystic Fibrosis (CF). CF is a severe disease caused by the loss of a key protein called CFTR (Cystic Fibrosis Transmembrane Conductance Regulator), which results in an improper mucus layer lining patient airways and impairs lung function. A novel therapeutic known as Trikafta, has proven much success in ameliorating the symptoms of CF in patients by targeting the CFTR protein directly. However, there remains a cohort of patients who are unresponsive to Trikafta treatment and are therefore in desperate need of novel therapeutics. We hypothesize that the development of novel companion therapies will act synergistically with Trikafta.
The tissues that line our airways are made up of many distinct cell types which contain the CFTR protein. Data collected by our laboratory revealed distinct cell types enriched in the CFTR protein as well as distinct partner proteins. However, it remains unknown how these unique cell types work to utilize these distinct proteins to maintain proper CFTR function. We believe that an improved understanding of this cell type specific regulation of CFTR will uncover novel druggable protein targets. I will utilize airway tissue models from real CF patients, which have been heavily validated by our laboratory, as the model for CFTR activity. I will use specialized microscopy techniques on these cultures to detect for the presence of distinct cell types and monitor the functional augmentation of CFTR relative to modulators of these distinct partnering proteins. Ultimately, these novel drug targets have the potential to work in synergy with currently available therapeutics to ameliorate the symptoms of CF in the non-responsive cohort of patients.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
D'Addario, Chiara M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~